GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diamyd Medical AB (FRA:DMN) » Definitions » Piotroski F-Score

Diamyd Medical AB (FRA:DMN) Piotroski F-Score : 1 (As of Dec. 12, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Diamyd Medical AB Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 1 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Diamyd Medical AB has an F-score of 1. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Diamyd Medical AB's Piotroski F-Score or its related term are showing as below:

FRA:DMN' s Piotroski F-Score Range Over the Past 10 Years
Min: 1   Med: 4   Max: 6
Current: 1

During the past 13 years, the highest Piotroski F-Score of Diamyd Medical AB was 6. The lowest was 1. And the median was 4.


Diamyd Medical AB Piotroski F-Score Historical Data

The historical data trend for Diamyd Medical AB's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diamyd Medical AB Piotroski F-Score Chart

Diamyd Medical AB Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 5.00 4.00 2.00 1.00

Diamyd Medical AB Quarterly Data
Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.00 N/A 2.00 3.00 1.00

Competitive Comparison of Diamyd Medical AB's Piotroski F-Score

For the Biotechnology subindustry, Diamyd Medical AB's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Diamyd Medical AB's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Diamyd Medical AB's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Diamyd Medical AB's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Aug24) TTM:Last Year (Aug23) TTM:
Net Income was -2.839 + -2.601 + -3.448 + -4.342 = €-13.23 Mil.
Cash Flow from Operations was -2.409 + -3.15 + -3.164 + -2.546 = €-11.27 Mil.
Revenue was 0.003 + 0.002 + 0.004 + 0.002 = €0.01 Mil.
Gross Profit was -0.096 + -0.068 + -0.077 + -0.071 = €-0.31 Mil.
Average Total Assets from the begining of this year (Aug23)
to the end of this year (Aug24) was
(17.428 + 22.829 + 20.135 + 21.356 + 18.946) / 5 = €20.1388 Mil.
Total Assets at the begining of this year (Aug23) was €17.43 Mil.
Long-Term Debt & Capital Lease Obligation was €2.68 Mil.
Total Current Assets was €13.89 Mil.
Total Current Liabilities was €3.49 Mil.
Net Income was -3.02 + -2.232 + -1.814 + -3.177 = €-10.24 Mil.

Revenue was 0.019 + 0.01 + 0.013 + 0.006 = €0.05 Mil.
Gross Profit was -0.043 + -0.09 + -0.058 + -0.08 = €-0.27 Mil.
Average Total Assets from the begining of last year (Aug22)
to the end of last year (Aug23) was
(22.497 + 18.495 + 15.705 + 13.763 + 17.428) / 5 = €17.5776 Mil.
Total Assets at the begining of last year (Aug22) was €22.50 Mil.
Long-Term Debt & Capital Lease Obligation was €1.34 Mil.
Total Current Assets was €11.92 Mil.
Total Current Liabilities was €1.68 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Diamyd Medical AB's current Net Income (TTM) was -13.23. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Diamyd Medical AB's current Cash Flow from Operations (TTM) was -11.27. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Aug23)
=-13.23/17.428
=-0.75912325

ROA (Last Year)=Net Income/Total Assets (Aug22)
=-10.243/22.497
=-0.45530515

Diamyd Medical AB's return on assets of this year was -0.75912325. Diamyd Medical AB's return on assets of last year was -0.45530515. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Diamyd Medical AB's current Net Income (TTM) was -13.23. Diamyd Medical AB's current Cash Flow from Operations (TTM) was -11.27. ==> -11.27 > -13.23 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Aug24)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Aug23 to Aug24
=2.677/20.1388
=0.13292748

Gearing (Last Year: Aug23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Aug22 to Aug23
=1.343/17.5776
=0.07640406

Diamyd Medical AB's gearing of this year was 0.13292748. Diamyd Medical AB's gearing of last year was 0.07640406. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Aug24)=Total Current Assets/Total Current Liabilities
=13.892/3.494
=3.97595879

Current Ratio (Last Year: Aug23)=Total Current Assets/Total Current Liabilities
=11.924/1.681
=7.09339679

Diamyd Medical AB's current ratio of this year was 3.97595879. Diamyd Medical AB's current ratio of last year was 7.09339679. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Diamyd Medical AB's number of shares in issue this year was 99.76. Diamyd Medical AB's number of shares in issue last year was 82.361. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=-0.312/0.011
=-28.36363636

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=-0.271/0.048
=-5.64583333

Diamyd Medical AB's gross margin of this year was -28.36363636. Diamyd Medical AB's gross margin of last year was -5.64583333. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Aug23)
=0.011/17.428
=0.00063117

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Aug22)
=0.048/22.497
=0.00213362

Diamyd Medical AB's asset turnover of this year was 0.00063117. Diamyd Medical AB's asset turnover of last year was 0.00213362. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+0+0+0+0+0
=1

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Diamyd Medical AB has an F-score of 1. It is a bad or low score, which usually implies poor business operation.

Diamyd Medical AB  (FRA:DMN) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Diamyd Medical AB Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Diamyd Medical AB's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Diamyd Medical AB Business Description

Traded in Other Exchanges
Address
Kungsgatan 29, Stockholm, SWE, SE-111 56
Diamyd Medical AB is a Sweden-based company engaged in the field of pharmaceutical development. It develops therapies using in-licensed substances glutamic acid decarboxylase (GAD) and GABA for the prevention or treatment of diabetes and other inflammatory diseases. The firm is focused on finding the cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cells and medical technology. Its product portfolio consists of Diamyd, for the treatment of autoimmune diabetes; Remygen, a regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 and type 1 diabetes.